SCHEMBL29429685

SCHEMBL29429685

N#Cc1ccccc1C[C@H](N)C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 3/20 0.56
NOS1 P29475 3/20 0.56
NOS2 P35228 3/20 0.56
DPP4 P27487 3/20 0.54
FAP Q12884 2/20 0.54
DPP8 Q6V1X1 2/20 0.54
DPP9 Q86TI2 2/20 0.54
SLC7A5 Q01650 3/20 0.53
PKM P14618 2/20 0.53
ALPI P09923 1/20 0.53
PTGS1 P23219 1/20 0.53
XIAP P98170 1/20 0.53
DPP7 Q9UHL4 1/20 0.52
MAPT P10636 3/20 0.48
KDM4E B2RXH2 2/20 0.48
MEN1 O00255 2/20 0.48
LMNA P02545 2/20 0.48
BLM P54132 2/20 0.48
PMP22 Q01453 2/20 0.48
KMT2A Q03164 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2030783 1.00 NOS3 (0.56) NOS3NOS1NOS2DPP4FAP
SCHEMBL42646 1.00 NOS3 (0.56) NOS3NOS1NOS2DPP4FAP
SCHEMBL42647 1.00 NOS3 (0.56) NOS3NOS1NOS2DPP4FAP
Hydrochloric Acid SCHEMBL25215525 0.98 NOS3 (0.55) NOS3NOS1NOS2DPP4FAP
SCHEMBL25718868 0.85 DPP4 (0.53) NOS3NOS1NOS2DPP4FAP
SCHEMBL28346433 0.84 KMT2A (0.53) DPP4FAPDPP8DPP9DPP7
SCHEMBL28710330 0.83 NOS3 (0.56) NOS3NOS1NOS2SLC7A5PKM
SCHEMBL28710331 0.83 NOS3 (0.56) NOS3NOS1NOS2SLC7A5PKM
SCHEMBL7382769 0.83 CYP1A2 (0.50) DPP4FAPDPP8DPP9DPP7
SCHEMBL10067850 0.82 NOS3 (0.49) NOS3NOS1NOS2DPP4FAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025128649-A1 A TRANSLATION-INDEPENDENT DIRECTED EVOLUTION STRATEGY TO ENGINEER AMINOACYL-TRNA SYNTHETASES TRUSTEES OF BOSTON COLLEGE (US) 2025-06-19 WO claimed
US-20260116855-A1 ORALLY ACTIVE MELANOCORTIN RECEPTOR-4 COMPOUNDS PALATIN TECHNOLOGIES INC (US) 2026-04-30 US disclosed
US-20260083852-A1 PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR UNIV CALIFORNIA (US) 2026-03-26 US disclosed
US-20260001924-A1 NEMO COILED COIL MIMICS AND METHODS OF USING SAME NEW YORK UNIVERSITY (US) 2026-01-01 US disclosed
US-12485182-B2 Proteoglycan mimetics for enhanced wound healing, angiogenesis, and vascular repair THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-12-02 US disclosed
US-12459894-B2 Orally active melanocortin receptor-4 compounds PALATIN TECHNOLOGIES, INC. (US) 2025-11-04 US disclosed
US-20250327074-A1 THE RARE CODON RECODING PLATFORM FOR NONCANONICAL AMINO ACIDS INCORPORATION IN MAMMALIAN CELLS SHAOXING INSTITUTE, ZHEJIANG UNIVERSITY (CN) 2025-10-23 US disclosed
US-12384813-B2 Polymer linked multimers of guanosine-3′, 5′-cyclic monophosphates MIRECA MEDICINES GMBH (DE) 2025-08-12 US disclosed
US-12371461-B2 Nemo coiled coil mimics and methods of using same NEW YORK UNIVERSITY (US) 2025-07-29 US disclosed
WO-2025128649-A1 A TRANSLATION-INDEPENDENT DIRECTED EVOLUTION STRATEGY TO ENGINEER AMINOACYL-TRNA SYNTHETASES TRUSTEES OF BOSTON COLLEGE (US) 2025-06-19 WO disclosed
EP-4021941-A1 A SINGLE-DOMAIN ANTIBODY FOR TARGETING PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) National Institute for Biotechnology in the Negev Ltd. (IL) 2022-07-06 EP disclosed
US-20220204450-A1 Orally Active Melanocortin Receptor-4 Compounds PALATIN TECHNOLOGIES, INC. (US) 2022-06-30 US disclosed
EP-4013440-A1 THERAPEUTIC PEPTIDES Cohbar Inc. (US) 2022-06-22 EP disclosed
US-11332497-B2 Therapeutic peptides COHBAR, INC. (US) 2022-05-17 US disclosed
EP-3983543-A1 REAGENTS AND METHODS FOR REPLICATION, TRANSCRIPTION, AND TRANSLATION IN SEMI-SYNTHETIC ORGANISMS The Scripps Research Institute (US) 2022-04-20 EP disclosed
WO-2022076334-A2 CLEANING COMPOSITION COMPRISING AN ALPHA-DIOXYGENASE THE PROCTER & GAMBLE COMPANY (US) 2022-04-14 WO disclosed
EP-3976635-A1 METHODS OF TREATING HYPERLIPIDEMIA CONDITIONS WITH NETRIN-1 COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-04-06 EP disclosed
CN-114269367-A Therapeutic peptides 科巴公司 2022-04-01 CN disclosed
WO-2022066534-A1 ENGINEERED BIOCATALYSTS AND METHODS FOR SYNTHESIZING CHIRAL AMINES CODEXIS, INC. (US) 2022-03-31 WO disclosed
EP-3966223-A1 PEPTIDOMIMETIC AGENTS, SYNTHESIS AND USES THEREOF The Feinstein Institutes for Medical Research (US) 2022-03-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12459894-B2 Orally active melanocortin receptor-4 compounds MC4R, MC1R, MC3R NOS3 3583/4885NOS1 3870/4885NOS2 4083/4885
US-12384813-B2 Polymer linked multimers of guanosine-3′, 5′-cyclic monophosphates PRKG1, PRKG2, PRKAG3 NOS3 1116/4885NOS1 1920/4885NOS2 1748/4885
US-12371461-B2 Nemo coiled coil mimics and methods of using same COIL, CALCOCO2, NCAPH NOS3 1914/4885NOS1 2370/4885NOS2 2393/4885
US-12485182-B2 Proteoglycan mimetics for enhanced wound healing, angiogenesis, and vascular repair PDGFA, PDGFRB, TEK NOS3 2114/4885NOS1 3356/4885NOS2 3488/4885
US-20260083852-A1 PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR PDGFA, DCLRE1A, PDGFRA NOS3 3771/4885NOS1 4059/4885NOS2 3967/4885
US-20260001924-A1 NEMO COILED COIL MIMICS AND METHODS OF USING SAME DDX21, PHAX, RBX1 NOS3 2583/4885NOS1 2359/4885NOS2 3034/4885
US-20220204450-A1 Orally Active Melanocortin Receptor-4 Compounds MC4R, MC1R, MC3R NOS3 3583/4885NOS1 3870/4885NOS2 4083/4885
US-20260116855-A1 ORALLY ACTIVE MELANOCORTIN RECEPTOR-4 COMPOUNDS MC1R, MC3R, MC5R NOS3 1703/4885NOS1 2290/4885NOS2 2831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.